Sanofi’s $3.7B Principia Buy Starts to Pay Off with Phase III Rilzabrutinib Win


Pictured: Sanofi’s signage outside its office in Quebec, Canada/iStock, JHVEPhoto

Sanofi on Tuesday announced that its investigational BTK inhibitor rilzabrutinib met the primary endpoint in the Phase III LUNA 3 study, eliciting durable platelet response in adult patients with persistent or chronic immune thrombocytopenia.

The pharma did not disclose specific data in its announcement but said that significantly more patients on rilzabrutinib versus placebo achieved durable platelet response, which LUNA 3 defines as having a minimum platelet count of 50,000/µL for at least eight of the last 12 weeks.

Sanofi called LUNA 3’s results “clinically and statistically significant.” The study also achieved positive outcomes on key secondary endpoints.

Houman Ashrafian, head of research and development at Sanofi, in a statement said that LUNA 3’s results “reinforce rilzabrutinib’s potential to be a first-in-class oral, reversible BTK inhibitor that can provide clinically meaningful improvements for…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks